TNF-α Induced Apoptosis is Accompanied with Rapid CD30 and Slower CD45 Shedding from K-562 Cells

Abstract

TNF-α can induce cell death (apoptosis and necrosis), and these effects mostly depend on expression of TNF-receptor superfamily molecules. As determination of certain intracellular enzymes like LDH, released from cultured tumor cells, reflects early membrane alterations, we compared LDH release with changes in cell surface membrane molecule expression during culture of K-562 cells in the presence of TNF-α. TNF-α-mediated CD45 and CD30 shedding is shown to be to be time- and dose-dependent and associated with significant increase in LDH release, with maximal effects after 24 h of treatment. The percentage of decrease of all examined cell surface molecules on K-562 cells after TNF-α treatment was not uniform and appeared to depend on the respective constitutive level of expression and molecule type. The presence of these molecules was confirmed in supernatants using Western blot analyses. These results indicated the complexity of events on the cell membrane, including early LDH release that is associated with a difference in shedding of CD30 and CD45. Shedding of CD30 occurs before apoptosis induction, while shedding of CD45 is associated with apoptosis.

Receptor-mediated activation of a proinsulin-transferrin fusion protein in hepatoma cells

“…3A), and (c) several known reagents that inhibit the Tf-TfR intracellular endocytic processing events (e.g., incubation at 16 °C, or in the presence of ammonium chloride, chloroquine, or nocodazole) resulted in a drastic inhibition in the conversion of ProINS-Tf to irINS-Tf (Fig 3B, C, and D). In addition, results of LDH release assay, which is an indicator of membrane integrity [22, 23], suggested that ProINS-Tf fusion proteins did not cause cell membrane destruction to release non-specific cytosolic proteases to the cell surface.…”

Decreased CD161 activating and increased CD158a inhibitory receptor expression on NK cells underlies impaired NK cell cytotoxicity in patients with multiple myeloma

“…There are rare data regarding these NK cell effector functions in patients with MM and it has been shown that lenalidomide, an immunomodulatory agent used in the therapy of this disease, enhances the NK cell arm of the immune response 32. As found in other advanced malignancies, NK cell dysfunction in patients with MM is probably the consequence of cytokine disbalance due to the prevalence of immunosuppressive cytokines such as IL-10, transforming growth factor β (TGFβ) and also IL-6, as well as other tumour-produced inhibitory factors 33 34. These cytokines are involved in tumour-derived immune dysfunction by upregulation of immunosuppressive T regulatory cells, myeloid-derived suppressor cells and enzymes that through different mechanisms, including downregulation of cytotoxic molecules, perforin and granzymes, inhibit NK cell-mediated tumour cytotoxicity 12…”

Significance of GRP78 expression in acute myeloid leukemias

“…Drug resistance is the main cause of therapy failure. It is a multifactor phenomenon which includes different mechanisms leading to evasion of apoptosis [14]. One of the proteins involved in this process is GRP78.…”